Astria Therapeutics stock price target raised to $26 by JMP on HAE program progress

Astria Therapeutics (ATXS) is experiencing heightened analyst confidence, with JMP Securities raising its price target to $26 and other firms maintaining bullish ratings up to $47, driven by robust clinical data for its lead hereditary angioedema (HAE) drug, navenibart. Recent ALPHA-SOLAR trial results demonstrated a 92% reduction in monthly attack rates, positioning navenibart as a potential market leader, particularly with its anticipated Q6M dosing regimen. This positive outlook is further supported by a new licensing agreement with Kaken Pharmaceutical for navenibart in Japan, valued up to $32 million, which provides non-dilutive funding for a drug JMP projects could achieve $1.5 billion in peak worldwide sales as it progresses toward Phase 3 data in early 2027.

Analysis

Analyst sentiment for Astria Therapeutics (ATXS) has turned strongly positive, primarily driven by compelling clinical progress for its lead hereditary angioedema (HAE) drug, navenibart. JMP Securities increased its price target to $26, citing new data supporting a competitive profile for both 3-month and 6-month dosing regimens. This is reinforced by recent ALPHA-SOLAR trial results showing a 92% mean reduction in monthly attack rates, prompting affirmations of 'Buy' and 'Overweight' ratings from firms like H.C. Wainwright and Cantor Fitzgerald, with price targets reaching as high as $47. A key differentiator highlighted by a physician survey is the expectation that navenibart’s 6-month regimen will become the most-preferred HAE prophylactic treatment. Financially, the company has secured non-dilutive funding through an exclusive licensing agreement with Kaken Pharmaceutical for up to $32 million to commercialize navenibart in Japan. While the valuation case, per JMP, hinges on navenibart achieving $1.5 billion in peak worldwide sales with an estimated 60% probability of success, the pipeline offers additional upside with Phase 1 data for its OX40 antibody, STAR-0310, expected this quarter. The most significant long-term catalyst remains the topline data from the Phase 3 study, anticipated in early 2027.

Key Decisions for Investors

• Given the compelling clinical data showing a 92% reduction in attack rates and a potentially best-in-class 6-month dosing schedule, investors with a high-risk tolerance may find Astria's upside attractive, as reflected in the wide range of bullish analyst price targets from $16 to $47.
• The primary value driver, navenibart, faces a significant waiting period, with pivotal Phase 3 data not expected until early 2027; therefore, investors must be prepared for a long-term holding period and the inherent clinical trial risks of a development-stage biotech.
• Monitor the release of Phase 1 data for the secondary asset, STAR-0310, this quarter, as positive results could provide a near-term upside catalyst and begin to de-risk the company's current dependency on navenibart.
• The licensing deal with Kaken Pharmaceutical provides non-dilutive capital, a positive signal for financial management, but investors should continue to track the company's cash burn rate relative to its long development timeline.